Add Off-target Risk Profiling to Your Analyses
Certara's cheminformatics solution, D360, supports a key feature of Secondary Intelligence: a low-medium-high ranking of…
Certara2026年1月5日
A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection
This study synthesizes data from a large body of clinical trials to evaluate rates of…
Certara2025年12月18日
Merck Advances Pediatric Oncology with Innovative ADC Modeling
Merck leveraged ADC modeling and pediatric ADC dose optimization to enable FDA acceptance and advance…
Certara2025年12月12日
Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling
Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…
Certara2025年11月10日
In silico Safety and Toxicology assessment: ToxStudio®
Discover how Certara’s ToxStudio align with FDA’s roadmap to reduce animal testing and transform preclinical…
Certara2025年10月30日
Get clear, practical answers to the top 5 safety reporting questions & learn how to…
Certara2025年10月7日
C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions
Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…
Certara2025年10月3日
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
Certara2025年10月2日
